1,3-DISUBSTITUTED BENZIMIDAZOL-2-ONE DERIVATIVE AS A DIPEPTIDYL PEPTIDASE-4 INHIBITOR
Abstract
The benzimidazole core is a valuable moiety among biologically active compounds, providing a synthetically tractable drug-like scaffold. Some benzimidazole derivatives with inhibitory potential against multifunctional aminopeptidase dipeptidyl peptidase-4 (DPP-4), a promising therapeutic target for type 2 diabetes, have been reported so far. After studying DPP-4 inhibitors with 1,3-disubstituted-benzimidazol-2-imine scaffold, the inhibitory activity of 1,3-disubstituted benzimidazol-2-one derivatives against DPP-4 was evaluated here. 5-Methyl-1,3-bis(2-oxo-2-phenylethyl)-1,3-dihydro-2H-benzimidazol-2-one (compound 5) inhibited this protease with IC50 value about 200 μM. Although not as potent an inhibitor, compound 5 might contribute to further design and optimizations of benzimidazole based DPP-4 inhibitors.
References
Ajani OO, Aderohunmu DV, Ikpo CO, Adedapo AE, Olanrewaju IO. Functionalized benzimidazole scaffolds: privileged heterocycle for drug design in therapeutic medicine. Archiv der Pharmazie 2016; 349(7): 475-506. [CrossRef][PubMed]
Anderluh M, Kocic G, Tomovic K, Kocic H, Smelcerovic A. DPP-4 inhibition: А novel therapeutic approach to the treatment of pulmonary hypertension?. Pharmacology and Therapeutics 2019; 201: 1-7. [CrossRef][PubMed]
Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smelcerovic A. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors. Pharmacology and Therapeutics 2016; 167: 100-7. [CrossRef][PubMed]
Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?. Journal of Medicinal Chemistry 2014; 57(6): 2197-212. [CrossRef][PubMed]
Kumar S, Mittal A, Mittal A. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. Bioorganic and Medicinal Chemistry 2021; 46: 116354. [CrossRef][PubMed]
Mavrova A, Anichina K, Izevbekhai O, Vutchev D, Popova-Daskalova G, Yancheva D, et al. New 1,3-disubsituted benzimidazol-2-ones as a promising scaffold for the antitrihinellosis agents development. Journal of Chemical Technology and Metallurgy 2021; 56: 3-9.
Tomovic K, Ilic BS, Miljkovic M, Dimov S, Yancheva D, Kojic M, et al. Benzo[4,5]thieno[2,3‐d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase‐4. Archiv der Pharmazie 2020; 353(1): 1900238. [CrossRef][PubMed]
Tomovic K, Ilic BS, Smelcerovic A. Structure–activity relationship analysis of cocrystallized gliptin-like pyrrolidine, trifluorophenyl, and pyrimidine-2,4-dione dipeptidyl peptidase-4 inhibitors. Journal of Medicinal Chemistry 2021; 64(14): 9639-48. [CrossRef][PubMed]
Tomovic K, Ilic BS, Smelcerovic Z, Miljkovic M, Yancheva D, Kojic M, et al. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. Chemico-Biological Interactions 2020; 315: 108873. [CrossRef][PubMed]
Tomovic K, Lazarevic J, Kocic G, Deljanin‐Ilic M, Anderluh M, Smelcerovic A. Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection. Medicinal Research Reviews 2019; 39(1): 404-22. [CrossRef][PubMed]
Wallace MB, Feng J, Zhang Z, Skene RJ, Shi L, Caster CL, et al. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters 2008; 18(7): 2362-7. [CrossRef][PubMed]
